Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn’s Disease at New York Academy of Sciences Symposium
Palisade Bio announced that its President and CMO, Dr. Mitchell Jones, will present on the potential of PALI-2108 for fibrostenotic Crohn’s disease at the New York Academy of Sciences symposium on June 9, 2026. The presentation will discuss the unmet need in fibrostenotic Crohn’s disease, the biology of intestinal fibrosis, and the rationale for PALI-2108 as a locally bioactivated PDE4 inhibitor prodrug.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.